10 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | MOSELEY II, NELSON B | 1642 | Non-Final OA | May 10, 2023 |
| 18297069 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | MELCHIOR, JAMES RYLAND | 1644 | Non-Final OA | Apr 07, 2023 |
| 18297076 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST LUNG CANCER, INCLUDING NSCLC, SCLC AND OTHER CANCERS | MERTZ, PREMA MARIA | 1674 | Non-Final OA | Apr 07, 2023 |
| 18297064 | PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | STOICA, ELLY GERALD | 1647 | Non-Final OA | Apr 07, 2023 |
| 18192743 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST OVARIAN CANCER AND OTHER CANCERS | JUEDES, AMY E | 1644 | Non-Final OA | Mar 30, 2023 |
| 18185649 | PEPTIDES AND COMBINATION OF PEPTIDES OF NON-CANONICAL ORIGIN FOR USE IN IMMUNOTHERAPY AGAINST DIFFERENT TYPES OF CANCERS | WU, JULIE ZHEN QIN | 1643 | Non-Final OA | Mar 17, 2023 |
| 18178055 | PERSONALIZED IMMUNOTHERAPY AGAINST SEVERAL NEURONAL AND BRAIN TUMORS | FONTAINHAS, AURORA M | 1675 | Non-Final OA | Mar 03, 2023 |
| 18160420 | A*03 RESTRICTED PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST CANCERS AND RELATED METHODS | YAO, LEI | 1642 | Non-Final OA | Jan 27, 2023 |
| 18154091 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | CANELLA, KAREN A | 1643 | Non-Final OA | Jan 13, 2023 |
| 18154098 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AND METHODS FOR GENERATING SCAFFOLDS FOR THE USE AGAINST PANCREATIC CANCER AND OTHER CANCERS | CANELLA, KAREN A | 1643 | Non-Final OA | Jan 13, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial